A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ Anstee QM Trauner M et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020;72:67A-68A. abstract 90.
- Ratziu V de Guevara L Safadi R et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized double-blind placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 601–700 of 830
Hidden Complication of Obesity and Diabetes: Is It Time to Put More Focus on Fatty Liver?
Kim, J. W., & Sebastiani, G. (2023) · EMJ Diabetes · doi:10.33590/emjdiabet/10307262 · Cited by 2
“NASH-Worldwide the Commonest Aetiology of Liver Cirrhosis”- a Review Article
Jannat, S. N. E., Islam, M. M. S. U., Haque, M. M., Imam, I., & Ahmed, D. S. (2023) · Bangabandhu Sheikh Mujib Medical College Journal · doi:10.3329/bsmmcj.v2i2.69844 · Cited by 2
“Peroxisome proliferator-activated receptors (PPARs)- Lanifibranor, is generally well tolerated with mild weight gain under phase III trial 134,135 .”
BackgroundUpdates in nonalcoholic fatty liver disease
Wungjiranirun, M., Wong, N., Jou, J. H., & Moylan, C. A. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000085 · Cited by 2
Is curcumin the new kid on the block for the treatment of MASH?
Zelber‐Sagi, S., & Schattenberg, J. M. (2024) · Hepatology · doi:10.1097/hep.0000000000000949 · Cited by 2
Self-citationShi, P., Chen, X., Cao, J., Feng, Z., & Xue, B. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073344422240906051007 · Cited by 3
Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
Francque, S., & Vonghia, L. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00306-6 · Cited by 2
Self-citationDiabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Stefan, N., & Roden, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2312-0452 · Cited by 2
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Luo, X., Lu, J., Shen, Z., Ge, Q., Zhangdi, H., Wang, J., Ye, Y., Zhang, L., Luo, Y., Qu, Y., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501007r · Cited by 2
“In addition, many drugs such as Lanifbranor developed by Inventiva, Semaglutide developed by Novo Nord, and Pegozafermin, a fibroblast growth factor 21 (FGF21) analogue developed by 89bio, all achieved good performance in clinical trial results [21–25].”
Non-Alcoholic Fatty Liver Disease and Steatohepatitis
Govaere, O., & Anstee, Q. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00265-0 · Cited by 2
Self-citationCorvec, M. L., Farrugia, M. A., Nguyen-Khac, É., Regimbeau, J., Dharhri, A., Chatelain, D., Khamphommala, L., Gautier, A.-L., Berre, N. L., Frey, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72704-5 · Cited by 2
Demidova, T. Y., Расуловна, Б. А., & Омариевна, У. Ф. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-09 · Cited by 1
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Self-citationMondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 2
“…patients with biopsy-proven MASH, the 1,200-mg dose of lanifibranor significantly decreased histologic Steatosis, Activity and Fibrosis (SAF) score by at least two points in up to 55% patients, along with reduction in liver enzymes, lipids, pro-inflammatory biomarkers and fibrosis test scores [11].”
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review
Ahmed, T., Farooq, S., Naveed, M. A., Shahzad, A., Rehman, W., Haider, T., & Noor, N. N. (2025) · Cureus · doi:10.7759/cureus.89969 · Cited by 2
Hwang, I., Lee, S. W., Kim, H. J., Kim, Y., & Lee, S. W. (2025) · Life · doi:10.3390/life15091410 · Cited by 1
“…including nuclear receptor ligands such as peroxisome proliferator-activated receptor (PPAR) agonists (e.g., lanifibranor), and de novo lipogenesis inhibitors such as acetyl-CoA carboxylase (ACC) inhibitors (e.g., firsocostat) and fatty acid synthase (FAS) inhibitors (e.g., TVB-2640) [13–15].”
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
The role of the PPAR system in diabetic cardiovascular risk and beyond
Ruscica, M., Macchi, C., Corsini, A., & Sirtori, C. R. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000943 · Cited by 1
Nuclear Receptor-Targeted Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease
Zhou, Y., Liu, Z., Cui, D., Qi, X., & Zhang, H. (2025) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2025.100024 · Cited by 1
“[80] [81,82] [83] [18,84] [22] [85] [86] [23] [87]”
Nonga, D., Chaves, E. A., Pandurangi, S., Hartjes, K. T., Chu, C., & Flores, A. (2025) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-025-00356-2 · Cited by 1
Ramírez-Mejía, M. M., Ponciano‐Rodríguez, G., Poo, J. L., & Méndez‐Sánchez, N. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103387 · Cited by 1
From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
Yu, H., Ding, H., Huang, Y., Cao, H., Ding, Y., & Wang, W. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70036 · Cited by 1
Zhou, G., Gu, X., Zhou, X., Chen, S., Liu, H., & Wang, J. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-002123 · Cited by 1
Kurzyna, P. F., Chabowski, P., Zwierz, M., Harasim‐Symbor, E., Dzięcioł, J., Klimek, J., Ryszkiewicz, P., Chabowski, A., & Konstantynowicz-Nowicka, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-41130-0 · Cited by 1
“Another important process impaired in MASLD is de novo lipogenesis, whose activity can be represented by the de novo lipogenesis ratio 44,45 .”
InfluentialPharmacological strategies targeting hepatocyte-mediated crosstalk in liver fibrosis
Zhang, Y., Wei, M., Zhou, X.-Y., Qi, L., & Liu, Q. Q. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.01.010 · Cited by 1
Deng, W., Yang, X., Wu, H., Tang, H., Wang, X., Tu, S., Yin, K., & Zhu, X. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02774-7 · Cited by 1
“…Lani-fibranor, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, became the first compound to achieve both NASH resolution and fibrosis improvement as a composite endpoint in the phase IIb NATIVE study, with rates of 45% and 42%, respectively, in the high-dose group [22].”
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 3
Self-citationMASH and liver fibrosis: Clinical trials to watch
Zhang, X., & Wong, V. W. (2026) · Med · doi:10.1016/j.medj.2026.101069 · Cited by 1
Sheng, R., Zhang, Y., Wang, J., Yang, G., Jiang, W., Ju, C., Li, S., Wang, C., Zhang, J., Lei, L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119008 · Cited by 2
吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
“…lanifibranor, pegozafermin, and other fibroblast growth factor 21 (FGF21) analogs have shown promising signals for improving MASH activity, reducing liver fat content, and promoting fibrosis regression (Francque S. M. et al., 2021; Sanyal et al., 2019; Loomba et al., 2023b; Harrison et al., 2023).”
MASLD as Complication of Diabetes
Stefan, N. (2026) · Diabetes · doi:10.2337/dbi26-0001 · Cited by 2
Zuo, H., Chen, J., Jiao, Y., Ma, X., Li, X., Xiao, Y., He, J., Jia, Z., & Shi, A. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1803228 · Cited by 1
Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment
Cui, Z., Du, X., Amevor, F. K., Xia, Y., Yang, Y., & Liu, L. (2026) · MedComm · doi:10.1002/mco2.70832 · Cited by 1
“These include peroxisome proliferator-activated receptor (PPAR) agonists, such as pioglitazone [ 92 ], lanifibranor [ 93 ], as well as glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide, which have demonstrated promising metabolic and hepatic benefits in clinical studies [ 94,…”
Zhao, R., Li, Y., Guo, T., Liu, D., Niu, S., Zheng, D., Qi, J., Sun, J., Feng, B. L., Wang, Z., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1864960 · Cited by 1
“Members of the PPAR family are integral in regulating hepatic fatty acid uptake, β -oxidation, and ketogen-esis, with PPAR α assuming a particularly significant role in these processes (24–26).”
Romeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 2
“Fenofibrate is one of the most widely used selective PPAR α agonists and has long been employed for the treatment of hypertriglyceridemia and mixed dyslipidemia [100–102].”
InfluentialMASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714267 · Cited by 1
Liu, J., & Wu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1879097 · Cited by 2
“Tirzepatide, pegozafermin, efruxifermin and lanifibranor have widened the development field, although they differ in mechanism, maturity of evidence and regulatory status (Francque et al., 2021; Loomba et al., 2023; Harrison et al., 2023; Loomba et al., 2024).”
Zhu, L., & Wu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899587 · Cited by 1
Younossi, Z. M., Papatheodoridis, G., Tsochatzis, E. A., Buti, M., Rimassa, L., Pinzani, M., Lleò, A., Shawcross, D. L., Tacke, F., Wong, V. W., et al. (2026) · Liver International · doi:10.1111/liv.70806 · Cited by 2
Self-citationUpcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Newsome, P. N., & Ajaz, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70143 · Cited by 2
The hepatic sinusoid as a regulatory niche: From cellular specialization to precision hepatology
Fernández‐Iglesias, A., Harris, E. N., Jalan‐Sakrikar, N., Kaur, S., Zapotoczny, B., Ikejima, K., & Gracia‐Sancho, J. (2026) · Hepatology · doi:10.1097/hep.0000000000001870 · Cited by 1
Investigational drugs in early clinical development for portal hypertension
Rodrigues, S. G., Mendoza, Y. P., & Bosch, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2095259 · Cited by 3
Ye, J., Qi, Y., Chen, J., Zhang, S., Liu, B., Zhao, Y., Yuan, X., Cheng, Q., Yang, Y., Zhang, F., et al. (2023) · Advanced Biology · doi:10.1002/adbi.202200150 · Cited by 1
From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis
Aggarwal, M., & Lindenmeyer, C. C. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000005 · Cited by 1
Traitement médical de la stéatohépatite métabolique en 2022
Masrour, O., & Bardou‐Jacquet, E. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.12.003 · Cited by 1
Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.007 · Cited by 1
Prognostic biomarkers in and selection of surgical patients with hepatocellular carcinoma
Pommergaard, H. (2023) · Apmis · doi:10.1111/apm.13309 · Cited by 1
“In a phase 2 trial, patients with NASH were randomized to receive Lanifibranor, a PPAR agonist or a placebo [112].”
BackgroundТкач, С. М., & Dogotar, V. B. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-2-34 · Cited by 1
“У фазі дослідження IIb у 247 пацієнтів, які отримували пан-PPAR-агоніст «Ланіфібранор», зафіксовано поліпшення НАСГ за зниженням принаймні на 2 бали при оцінці за системою SAF-A (частина системи оцінки стеатозу, активності, фіброзу) без погіршення фіброзу порівняно із плацебо (55 та 33 %) [46].”
Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
Mihai, C., Mihai, B. M., & Prelipcean, C. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_14 · Cited by 1
Praxisorientierte Strategien für Screening, Diagnostik und Therapie der NAFLD
Kreimeyer, H., Manka, P. P., & Canbay, A. E. (2023) · Gastro-News · doi:10.1007/s15036-023-3265-4 · Cited by 1
GW501516 (Cardarine): Pharmacological and Clinical Effects
Bianchi, V. E., & Locatelli, V. (2023) · Genetics & Molecular Medicine · doi:10.33425/2689-1077.1021 · Cited by 3
Stefan, N., & Roden, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6824 · Cited by 1
“The pan-PPAR (PPAR alpha, delta and gamma) agonist lanifibranor showed a marked im - provement in NASH and fibrosis in patients with NASH without cir - rhosis [23].”
BackgroundEmerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
Iwaki, M., Yoneda, M., Wada, N., Otani, T., Kobayashi, T., Nogami, A., Saito, S., & Nakajima, A. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2328036 · Cited by 1
“The pan-PPAR agonist lanifibranor met its primary endpoint of reducing SAF activity score by at least 2 points without worsening fibrosis in a 247-patient, 24-week phase-IIb trial (27% on placebo vs. 49% on 1200-mg lanifibranor) [51].”
BackgroundRole of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
Fernández‐Iglesias, A., & Gracia‐Sancho, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00023-1 · Cited by 1
Shen, Z., Cai, X., & Lu, L. G. (2024) · PubMed Central · doi:10.3760/cma.j.cn501113-20240227-00097 · Cited by 2
Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options
Śliz, J., Popławska, N. A., Skorupska, M., Czeczotka, M. J., Woźniak, K., & Martka, M. M. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52219 · Cited by 1
Zhang, Y., & Xu, C. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.1211015 · Cited by 1
Perspectives of Drug Therapy for Non-Alcoholic Steatohepatitis-Related Liver Fibrosis
Garbuzenko, D. V. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10002 · Cited by 1
Xue, C.-Y., Wu, L., Rao, C., Huang, X., Chen, S., & Li, F. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4345746 · Cited by 1
Alkhouri, N., Beyer, C., Shumbayawonda, E., Andersson, A., Yale, K., Rolph, T., Chung, R., Vuppalanchi, R., Cusi, K. J., Loomba, R. S., et al. (2024) · medRxiv · doi:10.1101/2024.02.28.24302571 · Cited by 2
Self-citationDoes the benefit of optimal MASH treatment depend on a reduction in myosteatosis?
Lanthier, N. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102640 · Cited by 1
Self-citationRomero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
Self-citationErgebnisse zum Einsatz von Lanifibranor bei NASH-Patienten vorgelegt
Lichert, F. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1696-8600
Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
van Kleef, L. A., & de Knegt, R. J. (2022) · Hepatology Communications · doi:10.1002/hep4.2006
“[2] Suppose the hypothesis for power calculation was based on one of the most promising anti- NAFLD drugs being investigated: The power was only 47% and 25% for detecting improvements in steatohepatitis and fibrosis, respectively.[3] Studies with relatively low power need to be interpreted with caution, as they are pr…”
BackgroundDrugs to Modify Liver Fibrosis Progression and Regression
Vilaseca, M., & Gracia‐Sancho, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_18
Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease
Yoshiji, H., Namisaki, T., Kaji, K., & Francque, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_19
Self-citation12-Year-Old-Girl with a White Indented Plaque of the Frontal Scalp and Forehead
Goldenberg, M., Noll, P., Sampath, S., & Trotter, S. C. (2022) · Clinical Cases in Dermatology · doi:10.1007/978-3-031-15820-9_18
Rapport 23-02. Le foie stéatosique non alcoolique : un défi de santé publique
Brissot, P., & Buffet, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.014 · Cited by 3
New approaches in the diagnosis and treatment of non-alcoholic fatty liver disease.
Sergienko, O. I., Oparin, A. G., & Novokhatnya, А. E. (2023) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2023.02.012
Song, Y., Zheng, M., Sheng, H., Wang, J., Xie, S., Yang, Y., Chi, X., Chen, J., He, F., Fan, X., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4496126
Transcription factors in abnormal metabolism and inflammatory of NAFLD
Ni, Y. (2023) · Open Journal of Clinical and Medical Images · doi:10.52768/2833-2725/1093
Emerging Treatments for Patients With Nonalcoholic Steatohepatitis.
Ratziu, V. (2023) · PubMed Central · Cited by 1
Self-citationPromoting Liver Regeneration by Utilizing Liver Macrophage Metabolism
刘, 云. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141049
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Stefan, N., & Roden, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01170-4
Sauerbruch, T., & Trebicka, J. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21005-1.00057-3
Role of Kupffer cells and other immune cells
Puengel, T., & Tacke, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00024-3
The liver sinusoid in chronic liver disease: NAFLD and NASH
Kwanten, W. J., & Francque, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00012-7
Self-citationBarb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Lucile, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4840179
Self-citationPharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Development of Therapy for Liver Fibrosis: Molecular/cellular basis and overcoming challenges
Inagaki, Y., & Yanagawa, T. (2024) · Kanzo · doi:10.2957/kanzo.65.305
Approach to Weight Loss Patient's Post Bariatric Surgery
AlSaeed, A., Algazwi, H., Alsahhaf, M., Alhulail, S., Alsharafaa, A., Alsheef, M. A., Aljowaiher, B., Bomozah, H., Mubarak, A. A., Aldaghdough, H., et al. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24619141101
Manka, P. P., Kreimeyer, H., & Canbay, A. E. (2024) · Gastroenterologie up2date · doi:10.1055/a-2123-0462
Enfermedad de hígado graso no alcohólico. Un enfoque multidisciplinario
de Tamaulipas, U. A., Pérez, B. G., Flores, R. S., de Tamaulipas, U. A., Escobedo, R. D. L., de Tamaulipas, U. A., García, J. A., & de Tamaulipas, U. A. (2024) · doi:10.29059/luat.373 · Cited by 1
The Developments of Drugs Based on Non-Alcoholic Fatty Liver
Chen, S., & Chu, M. (2024) · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research · doi:10.2991/978-2-38476-295-8_17
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
Abdel-Samiee, M., Ibrahim, E. S., Kohla, M., Abdelsameea, E., & Salama, M. (2024) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v15.i6.97381
The Multifaced Roles of Hepatic Macrophages in MASLD
Sui, X., Wu, M., Yang, X., & Wang, Y. (2024) · Health and Metabolism · doi:10.53941/hm.2024.100004
Histopathology of MASLD: Insights into Liver Tissue Changes
Francque, S., & Driessen, A. L. C. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_6 · Cited by 2
Self-citationBril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69 · Cited by 1
Etude du lien entre la MASLD et l'athérosclérose : implication du récepteur nucléaire PPARα
Henry, D. (2024) · theses.fr (ABES) · doi:10.70675/573969cdz9f43z407fz8775zbacc66020c5a
Hallazgos por imagen de las enfermedades hepáticas por depósito
Rouilleault, A. C. I., Jiménez, S. M., Moreno, J., Belmonte, E., Ayuso, J. R., & García‐Criado, Á. (2025) · Radiología · doi:10.1016/j.rx.2025.02.005
NASH Cirrhosis: A Systematic Review of Phase 2B Trials
Singh, B., Ramanan, S. P., Singh, W., Kaur, G., Grover, P., & Sridhar, N. (2025) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2025.154014
The Role of Nuclear Receptor PPAR in Liver Fibrosis
思, 璐. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541071
Kowalczyk, E., Gorczyca-Głowacka, I., Stupecki, G., Ciba-Stemplewska, A., Dolecka-Ślusarczyk, M., & Wolak, P. (2025) · Clinical Diabetology · doi:10.5603/cd.104353 · Cited by 2
Gilgenkrantz, H. (2025) · médecine/sciences · doi:10.1051/medsci/2025051
Optimising Dietary Interventions for MASLD: A Nutritional Perspective on Liver Heath
Lamba, S., & Bhavana, S. (2025) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2025.v07i03.46465
“Lanifibranor, a pan-PPAR agonist, met key endpoints in a Phase 2b trial, with nearly half of patients seeing fibrosis improvement [39] Saroglitazar, approved in India, improved liver enzymes and fat content in a short-term RCT [40] Aramchol, which targets fatty acid metabolism, showed moderate…”
Diabetes und metabolische-Dysfunktion-assoziierte steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01346-6
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.